Maintaining Participant Contact: June-December 2015 and Results dissemination
|
|
|
- Edward Henry
- 6 years ago
- Views:
Transcription
1 Maintaining Participant Contact: June-December 2015 and Results dissemination Krina Reddy (M.Med Sci) - Study Coordinator Wits Reproductive Health and HIV Institute (Wits RHI) MTN Annual Meeting 2015 Bethesda North Marriott Hotel & Conference Center, Maryland, USA 15 March 2015
2 OUTLINE Introduction Plans for maintaining participant contact Plans for results dissemination Summary Acknowledgments
3 INTRODUCTION Maintaining contact with participants after termination from the study is critical: Optimize ASPIRE result dissemination Optimize screening and enrolment into MTN 025 (HOPE) Participants enrolled: 213 Participants in follow up: 198 Why the discrepancy? Transferred out 4 [To Cape Town (2) & Zimbabwe sites (2)] Transferred in 6 [From Zimbabwe (2), Cape Town (1) & Durban (3) sites ] Termination 17 Aim is to maintain regular contact with all 198 participants
4 MAINTAINING CONTACT : CURRENT Cohort allocation system Community Health Workers (CHWS) Maintain regular contact phone calls, SMS, IM (WhatsApp) Participant/staff rapport Reminders for study visits, special events and general check in Update locator information System has been successful 96% retention excluding early terminations 91% retention overall Monitored by Community Liaison Officer (CLO), Study Coordinator (SC) & IoR IoR, SC, Clinians & CLO also contact participants as needed
5 PLANS FOR MAINTAINING CONTACT During study follow up: In daily waiting room discussions, Timelines to result dissemination Possibility of HOPE study Importance of maintaining site/participant contact is stressed At Product Use End Visit (PUEV ) and Study Exit Visit (SEV) Locator information updated Reminder to contact site as needed Future contact log completed (SEV) Contact card (SEV)
6 PLANS FOR MAINTAINING CONTACT After SEV: CHW will continue with regular contact with participants per allocation system for general check-in & locator update as needed. Holiday and Birthday listing to wish participants Use of bulk SMS system, IM (WhatsApp), telephone call Site events (e.g. Movie Day, End of Study Party)
7 PLANS FOR MAINTAINING CONTACT After SEV: Protocol currently being drafted to offer Monthly HIV testing and counseling, pregnancy testing as well as contraception counseling and provision as needed. HIV tests & contraception Gauteng Department of Health (DOH) - free Pregnancy test Currently checking with DOH Will only be implemented following IRB approval
8 PLANS FOR RESULT DISSEMINATION Participants will be provided with feedback with regards to availability of results Bulk SMS or at site events Result Dissemination: Study exit worksheet reponses will be used Review Study Exit Worksheets Create listing Plan for providing participant with final study results Method by which participant wishes to be contacted when study results are available Analyze listing Planned and schedule result dissemination Use communication material supplied by MTN
9 PLANS FOR RESULT DISSEMINATION Options for result dissemination to participants Group discussions Individual discussions /SMS/Instant Messaging/Telephone call Options for result dissemination to CAB & Stakeholders (as per the ASPIRE communications plan) Meetings Letters
10 SUMMARY Regular contact with participants must be maintained Site will continue with cohort allocation approach Regular telephonic check-in and update of locator information Face to face activities at site (e.g Movie Day) Possibly provision of monthly VCT, Pregnancy testing and contraception Concerted effort will be made to maintain contact with all 198 participants
11 ACKNOWLEDGMENTS Wits RHI Staff, Participants & Partners, Community Advisory Board (CAB), ASPIRE study sites The Microbicide Trials Network is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
CHARISMA s Impact on HOPE participants at Wits RHI
CHARISMA s Impact on HOPE participants at Wits RHI MTN Regional Meeting, The Westin Hotel, Cape Town, South Africa 21 September 2017 Thesla Palanee-Phillips, PhD, MSc Wits RHI Outline Background What is
MTN 034/IPM 045: REACH Rings and PrEP in Young Women
MTN 034/IPM 045: REACH Rings and PrEP in Young Women Lulu Nair CRS Leader: Emavundleni -Cape Town On behalf of MTN 034 protocol team MTN Annual Meeting: 2017 Bethesda North Marriott Hotel and Conference
MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
HIV Prevention Tools: What does the Community Say?
HIV Prevention Tools: What does the Community Say? Brenda Gati Mirembe, MBChB, MSc Epi Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda MTN Regional Meeting, Cape Town,
Welcome and State of the Network. Cape Town, South Africa 27 th September 2016
Welcome and State of the Network Cape Town, South Africa 27 th September 2016 The HIV/AIDS Epidemic in 2016 17 million people were accessing antiretroviral therapy 36.7 million people globally were living
What We Will Learn From the REACH Study
What We Will Learn From the REACH Study Lulu Nair (MBChB, MPH) MTN 034/IPM 045 Protocol Chair On behalf of protocol team 19 Sep 2017 MTN Regional Meeting 2017 Cape Town Overview Importance / Value of REACH
MTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012
MTN-020 and IPM 027 and the MTN-020 DSMB Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 Developing a range of options for antiretroviral-based HIV prevention Pill
ASPIRE Overview Where we are today
ASPIRE Overview Where we are today Flavia Matovu Kiweewa, MBChB, Msc. Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration Beyond Phase III: Seeking civil society perspectives on
A Zimbabwean Experience
1994-2014. Celebrating 20 years of cutting edge research Rumours, Myths and Misconceptions in ASPIRE: A Zimbabwean Experience Nyaradzo M Mgodi (MBChB, MMed) On behalf of the Zimbabwean ASPIRE Study Team
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
HIV PREVENTION RESEARCH UNIT
HIV PREVENTION RESEARCH UNIT STRATEGIES FOR ENGAGING COMMUNITIES IN MICROBICIDE RESEARCH: EXPERIENCES, ACCOMPLISHMENTS AND LESSONS LEARNED GITA RAMJEE MTN Annual Meeting: 22 April 2008 DESCRIPTION OF COMMUNITY
MTN 003 MONTHS 1 & 2 VISIT PRESENTATION ZIMBABWE TEAM JULIET MOYO RESEARCH NURSE MARTHA MASAWI COUNSELLOR
MTN 003 MONTHS 1 & 2 VISIT PRESENTATION ZIMBABWE TEAM JULIET MOYO RESEARCH NURSE MARTHA MASAWI COUNSELLOR CLINIC CLERK Greet participant. Create rapport Confirm PTID with Screening and Enrollment Log vs
Section 11. Counseling Procedures
Section 11. Counseling Procedures 11.1 HIV Counseling... 11-1 11.2 Protocol Counseling... 11-2 11.2.1 Contraception Counseling... 11-3 11.2.2 Protocol Adherence Counseling... 11-4 11.2.3 Product Use Counseling...
QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
QUESTIONS AND ANSWERS
CONTACTS: Clare Collins Lisa Rossi +1-412-641-7299 +1-412-641-8940 +1-412-770-8643 (mobile) +1-412-916-3315 (mobile) collcx@upmc.edu rossil@upmc.edu QUESTIONS AND ANSWERS MTN-016: HIV Prevention Agent
PrEP in young African women: Rationale & lessons from HPTN 082 (and other studiesp
PrEP in young African women: Rationale & lessons from HPTN 082 (and other studiesp Connie Celum MD MPH Departments of Global Health and Medicine University of Washington Disproportionate Success in Epidemic
QUESTIONS AND ANSWERS
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use The Big Picture 1. What is the aim of
Section 5. Study Procedures
Section 5. Study Procedures 5. Introduction 5-1 5.1 Visit Locations... 5-1 5.2 Eligibility Determination SOP... 5-1 5.3 Screening Visit... 5-2 5.3.1 Screening and Enrollment Timeframe... 5-2 5.3.2 Screening
PrEP in young African women: Rationale & lessons from HPTN 082
PrEP in young African women: Rationale & lessons from HPTN 082 Connie Celum MD MPH Departments of Global Health and Medicine University of Washington Disproportionate Success in HIV Epidemic Control by
IMPAACT Pregnant Woman by Cuth. Different Pieces of the Puzzle Lynda Stranix-Chibanda for the protocol team 25 September 2018, Cape Town
IMPAACT 2009 Pregnant Woman by Cuth Different Pieces of the Puzzle Lynda Stranix-Chibanda for the protocol team 25 September 2018, Cape Town HIV Prevention Puzzle How to prevent new HIV infections? Prevention
QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use I. ASPIRE and The Ring Study: The Basics
Understanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
Summary of Expected Insights on Oral PrEP for AGYW from Demo Projects in South Africa
March 2017 Summary of Expected Insights on Oral PrEP for AGYW from Demo Projects in South Africa Wits RHI in partnership with FSG and AVAC Work in progress for discussion Introduction A number of questions
FHI Study 10015: FEM-PrEP
FHI Study 10015: FEM-PrEP Phase 3, multi-center, double-blind, randomized, placebo-controlled effectiveness and safety study to assess the role of Truvada in preventing HIV acquisition in women MTN Annual
Behavioral Research in the Microbicide Trials Network
Behavioral Research in the Microbicide Trials Network HANC Behavioral Sciences Working Group Symposium Miami June 8, 2014 Ariane van der Straten, PhD, MPH Member, MTN Behavioral Research Working Group
The Kisumu Clinical Research Site. Mumbi Makanga MBChB, MPH MTN Regional Meeting 28 th September 2016
The Kisumu Clinical Research Site Mumbi Makanga MBChB, MPH MTN Regional Meeting 28 th September 2016 Overview History of the Kisumu CRS Communities Served by the Kisumu CRS Completed Studies / Clinical
OUTCOMES OF INFANTS STARTING ANTIRETROVIRAL THERAPY IN SOUTHERN AFRICA,
OUTCOMES OF INFANTS STARTING ANTIRETROVIRAL THERAPY IN SOUTHERN AFRICA, 2004-2012 Mireille Porter 1 *, Mary-ann Davies 1, Muntanga K. Mapani 2, Helena Rabie 3, Sam Phiri 4, James Nuttall 5, Lee Fairlie
Section 5. Study Procedures
Section 5. Study Procedures 5.1 Visit Locations... 1 5.2 Eligibility Determination SOP... 1 5.3 Screening Visit... 1 5.3.1 Screening and Enrollment Timeframe... 2 5.3.2 Screening Visit Procedures... 2
Partners in Prevention Lessons Learned Importance of Network Culture & Feedback Relevance for MTN
Partners in Prevention Lessons Learned Importance of Network Culture & Feedback Relevance for MTN MTN Annual Regional Meeting, Cape Town September 2008 Connie Celum, MD, MPH Clinical trials require. Important,
Section 6. Participant Follow-up
Section 6. Participant Follow-up Table of Contents 6.1 Study Follow-up Plan and Participant Retention Targets 6.2 Types of Follow-up Visits 6.3 Follow-up Visit Locations 6.4 Follow-up Visit Procedures
Update on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
Update on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot
SANCA DURBAN ALCOHOL AND DRUG CENTRES
STEERING COMMITTEE MEETING : DEVELOPING SERVICE QUALITY MEASURES FOR SUBSTANCE ABUSE IN SOUTH AFRICA LAGOON BEACH HOTEL, CAPE TOWN 25-26 NOVEMBER 2008 INTEGRATING HIV ISSUES INTO DRUG TREATMENT SERVICES
LETTER OF AMENDMENT #2 TO: MTN-036/IPM 047. A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings
LETTER OF AMENDMENT #2 TO: MTN-036/IPM 047 A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings Version 1.0, dated 28 June 2017 DAIDS Protocol #30009 IND
Section 6. Participant Follow-up
Section 6. Participant Follow-up Table of Contents 6.1 Study Follow-up Plan 6.2 Types of Follow-up Visits 6.3 Follow-up Visit Locations 6.4 Follow-up Visit Procedures 6.4.1 Visits to Pick Up Rings During
Novel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
Clinical Trials Network
National Drug Abuse Treatment Clinical Trials Network REDUCING THE RISK OF HIV AND HEPATITIS-C INFECTION: A RESEARCH STUDY Should I Sign Up? NATIONAL INSTITUTES OF HEALTH U.S. DEPARTMENT OF HEALTH AND
Contextual influences on product preference : Lessons from MTN studies
Contextual influences on product preference : Lessons from MTN studies Ariane van der Straten, PhD, MPH Women s Global Health Imperative RTI International San Francisco, CA, USA NIH: The role of relationships
HOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town
HOPE Follow-Up Algorithm: Unusual Cases Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town MTN-025 Testing Algorithm Screening/Enrollment MTN-025 Testing Algorithm
The Open Label Trial Past and Present
The Open Label Trial Past and Present Jared Baeten, M.D., Ph.D. University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention in
Hormonal contraception and HIV risk
Hormonal contraception and HIV risk Jared Baeten, MD, PhD Departments of Global Health, Medicine, and Epidemiology, University of Washington On behalf of the ECHO Consortium HPTN Annual Meeting Washington
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone
The Open Label Trial Past and Present
The Open Label Trial Past and Present Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention
INTERNATIONAL WORKSHOP ON HIV PEDIATRICS - JULY
PHARMACOKINETIC AND 4-WEEK SAFETY/EFFICACY OF DOLUTEGRAVIR (S/GSK1349572) DISPERSIBLE TABLETS IN HIV-INFECTED CHILDREN AGED 4 WEEKS TO
If the HPTN 082 protocol is amended in the future, this Letter of Amendment will be incorporated into the next version.
Letter of Amendment #3 to: HPTN 082: Uptake and adherence to daily oral PrEP as a primary prevention strategy for young African women: A Vanguard Study Version 1.0, 8 December 2015 DAIDS Document ID: 12068
Counseling for Choice
Counseling for Choice Iván C. Balán, Ph.D. Assistant Professor of Clinical Psychology Columbia University College of Physicians & Surgeons Research Scientist HIV Center for Clinical and Behavioral Studies
Section 5. Study Procedures
Section 5. Study Procedures Section 5. Study Procedures... 5-1 5 Introduction... 5-1 5.1 Visit Location... 5-1 5.2 Eligibility Determination and SOP... 5-2 5.3 Screening Visit... 5-2 5.3.1 Screening Visit
An Update on FACTS 001. Prof Helen Rees FACTS Protocol Chair
An Update on FACTS 001 Prof Helen Rees FACTS Protocol Chair FACTS 001 A Phase III, Multi-Centre, Randomised Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir
DEPARTMENT OF HEALTH RESPONSE TO KEY POPULATIONS
DEPARTMENT OF HEALTH RESPONSE TO KEY POPULATIONS KEY POPULATIONS PREVENTION INTERVENTIONS Ms E Marumo HIV PREVENTION STRATEGIES 13 June 2017 1 Background SA has about 7.1 million people living with HIV
Advocacy Impact: How to get started. Growing a Grassroots Network. HCBS Conference Sept. 13, 2011
Advocacy Impact: How to get started Growing a Grassroots Network HCBS Conference Sept. 13, 2011 1 What will you need? Your Model Leadership Passionate, key staff Great self advocates Power and a budget
Where are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
HPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission
HPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission TWEET LIVE #HPTN071 DIAL IN NUMBER FOR AUDIO: 1-866-740-1260 BROADCAST AUDIO CODE: 4011527 PLEASE USE THE CHAT
Follow-up Visit Procedures MTN-009
Follow-up Visit Procedures MTN-009 General Overview MTN-009 follow-up visits are only required for participants who are found to be HIV infected These participants will have a minimum of two follow-up
Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110
Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection: IMPAACT P1110 Clarke DF, Acosta EP, Chain A, Cababasay M, Wang J, Calabrese K, Spector SA, Bryson
Toolbox for conducting integrated HIV bio-behavioral surveillance (IBBS) in key populations Improving health and reducing inequities worldwide
Toolbox for conducting integrated HIV bio-behavioral surveillance (IBBS) in key populations Improving health and reducing inequities worldwide Copyright The Regents of the University of California, 2014.
Stunting and growth development for adolescents perinatally infected by HIV: males and females evolve differently.
Stunting and growth development for adolescents perinatally infected by HIV: males and females evolve differently. A multiregional analysis from the IeDEA global pediatric collaboration. Julie Jesson,
South African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
The Johns Hopkins Bloomberg School of Public Health
The Johns Hopkins Bloomberg School of Public Health CONSENT FORM A / NEW RESEARCH PROJECT Title of Research Project: A Randomized Trial of HAART in Acute/Early HIV Infection Version 3.0 Principal Investigator:
SINDAWONYE Clinical Trials Unit
HIV PREVENTION RESEARCH UNIT SINDAWONYE Clinical Trials Unit (we are together) GITA RAMJEE MTN Regional Meeting, Cape Town, South Africa 21-24 May 2007 CHATSWORTH CRS POPULATION CHARACTERISTICS CHATSWORTH
EXPERIENCES WITH BROADENING THE CONTRACEPTIVE MIX AT THE CAPRISA ETHEKWINI CRS
EXPERIENCES WITH BROADENING THE CONTRACEPTIVE MIX AT THE CAPRISA ETHEKWINI CRS MTN REGIONAL MEETING October 2013 Ishana Harkoo Overview Background IUCD Implementation Plan (i) Participant and Community
Good Participatory Practice guidelines
Good Participatory Practice guidelines Prevention Research Advocacy Mentoring and Education Program (PRAMEP) 2 August 2008 Discussion: Is it important to have community representatives participate in the
ANNEX A PANDEMIC INFLUENZA PLANNING
PANDEMIC INFLUENZA PLANNING Revised Plan DRAFT #5 August 2010 Pandemic Table of Contents 1. OHPIP Organizational Chart 2. NWHU Organizational Chart for Pandemic 3. NWHU Internal and External Functions
Section 10. Counseling Procedures
Section 10. Counseling Procedures 10.1 HIV Pre-and Post-Test Counseling... 1 10.2 HIV/STI Risk Reduction Counseling... 3 10.3 Contraceptive Counseling... 4 10.4 Protocol Adherence Counseling... 5 10.4.1
Catherine Martin. Abstract #157. SA AIDS Conference. June 2017
Catherine Martin SA AIDS Conference Integrated sexual and reproductive health services as an entry point to HIV testing, prevention and care for adolescent girls and young women in Johannesburg, South
MATERNAL AND CHILD SURVIVAL MEMORANDUM OF CONCERN
MATERNAL AND CHILD SURVIVAL MEMORANDUM OF CONCERN We, the undersigned would like to raise our urgent concerns about the quality and coverage of prevention of mother-to-child transmission of HIV (PMTCT)
The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa
The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa HPTN 075 Protocol Chair: Theo Sandfort New York State Psychiatric Institute and Columbia University
Our dental plan for individuals age 65 and over
2016 Dental plan information Our dental plan for individuals age 65 and over bcbsnc.com/dentalblueseniors What you get 1 + Affordable premiums with easy ways to pay + Two checkups and cleanings covered
APPENDIX B TAP 31 RESOLUTION PROCESS
I. General Principles APPENDIX B TAP 31 RESOLUTION PROCESS a. Administration: The TAP 31 Resolution Process is administered by the University s Title IX Coordinator and the University s Deputy Title IX
Women s Inclusion in HIV Clinical Research: Challenges and Successes
Women s Inclusion in HIV Clinical Research: Challenges and Successes Mary Allegra Cermak ACTG Community Coordinator Sharon Maxwell Henkel Women s HIV Research Collaborative Co-Chair Annet Davis-Vogel Women
Bringing Value to Research: Engaging Patients and Caregivers in Palliative Care Research. Susan Enguidanos, PhD
Bringing Value to Research: Engaging Patients and Caregivers in Palliative Care Research Susan Enguidanos, PhD 2 Acknowledgements/Disclosures Research reported in this presentation was funded through a
MTN-020/ASPIRE: Beginning to End and Just the Beginning
MTN-020/ASPIRE: Beginning to End and Just the Beginning Jared Baeten MD PhD & Thesla Palanee-Phillips PhD for the MTN-020/ASPIRE Study Team MTN Annual Meeting, March 2016 MTN-020/ASPIRE Study Team MTN-020/ASPIRE
8 th South African Aids Conference 2017
Health Systems Navigators - improving access to public sector HIV and sexual and reproductive health services among female sex workers in KwaZulu-Natal 8 th South African Aids Conference 2017 Letitia Greener*,
E.P.H.C RURAL TANZANIA REPORT KAHAMA HIV/AIDS HIGH RISK GROUPS TRAINING FORUM
E.P.H.C RURAL TANZANIA REPORT KAHAMA HIV/AIDS HIGH RISK GROUPS TRAINING FORUM 2 nd DECEMBER, 2012 Forum Held At Pine ridge Hotel- KAHAMA 2 nd December 2012 Prepared by: E.P.H.C rural Tanzania E.P.H.C RURAL
Impact of Learning HIV Status on Contraceptive Use in the MIRA Trial
Impact of Learning HIV Status on Contraceptive Use in the MIRA Trial Kelly Blanchard, Kelsey Otis, Alan Bostrom, Ariane van der Straten, Gita Ramjee, Guy de Bruyn, Tsungai Chipato, Elizabeth T Montgomery,
HVTN 505 Study HIV Vaccine Candidate Not Effective
Subscribe Unsubscribe HVTN 505 Study HIV Vaccine Candidate Not Effective The National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network have announced there will be
Interventions to improve PrEP and ART uptake and adherence among adolescent girls and young women. Jessica Haberer, MD, MS 26 April 2018
Interventions to improve PrEP and ART uptake and adherence among adolescent girls and young women Jessica Haberer, MD, MS 26 April 2018 Potential Conflicts and Financial Disclosures I have no actual or
SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING
SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING SCREENING AND ENROLLMENT VISITS Screening/ Visit 1 Eligibility Criteria initially assessed Multiple visits, if needed (Split visit)
Acceptability of HPTN 077. The George Washington University HPTN Clinical Research Site 16 June 2016
Acceptability of HPTN 077 The George Washington University HPTN Clinical Research Site 16 June 2016 Outline The epidemic in DC Prior HPTN studies, the context for injections Our experience with HPTN 077
The HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018
The HIV Prevention Product Pipeline for Adolescents SYBIL HOSEK, PHD DEPARTMENT OF PSYCHIATRY, STROGER HOSPITAL OF COOK COUNTY I NTER-CFAR ARV FOR PREVENTION WORKING GROUP WEBINAR JANUARY 8 TH, 2018 Conflicts
Los Angeles County PATH: PrEP and TLC+ for HIV Prevention. PATH Community Advisory Board Member Application
Los Angeles County PATH: PrEP and TLC+ for HIV Prevention PATH Community Advisory Board Member Application We would like to invite you to become a member of the PrEP and TLC+ for HIV Prevention (PATH)
Quality of Life of HIV-infected Patients Study
Investigator Name: Quality of Life of HIV-infected Patients Study OptumInsight is seeking for additional investigators for a multicenter longitudinal observational study involving adult patients with HIV.
Caregiver depression and child neuropsychological outcomes in an observational study of pediatric HIV carried out in four sub-saharan countries
Caregiver depression and child neuropsychological outcomes in an observational study of pediatric HIV carried out in four sub-saharan countries Itziar Familiar, Miriam Chernoff, Horacio Ruisenor-Escudero,
Hormonal contraceptive methods & HIV acquisition in women: updated systematic review of epidemiological evidence
Hormonal contraceptive methods & HIV acquisition in women: updated systematic review of epidemiological evidence CHELSEA B. POLIS, PHD SEPTEMBER 16, 2016 AVAC WEBINAR GUTTMACHER INSTITUTE 2016 Acknowledgements
Volunteer Initiative: Training Your Volunteers. Elizabeth Steimel, LCSW
Volunteer Initiative: Training Your Volunteers Elizabeth Steimel, LCSW Economic Security Initiative Volunteers started with ESI program Recruited from local newsletters, newspapers, VolunteerMatch and
Overview of Enrollment/Initiate Period 1 Visit Procedures
Overview of Enrollment/Initiate Period 1 Visit Procedures What should occur between the Screening and Enrollment visits? Review lab results Chemistries (AST/ALT and Creatinine) CBC with differential and
Best Practices for maintaining relationships with CBOs & stakeholders providing services to MSM and/or transgender people
Best Practices for maintaining relationships with CBOs & stakeholders providing services to MSM and/or transgender people Perspectives from Cape Town Area Joshua M. Kikuvi Desmond Tutu HIV Foundation Cape
Action Steps (B) Measures (C) Targets (D)1 Timeline (E)2 Responsible Parties (F) Progress (G)
HRSA Goal A1 Training and Technical Assistance Plan readiness of the clinic to increase its HIV services and offerings Action Steps (B) Measures (C) Targets (D)1 Timeline (E)2 Responsible Parties (F) Progress
2010 Sharing Hope Program for men
2010 Sharing Hope Program for men Criteria and Application Made possible by participating sperm banks and fertility centers Program Overview Goal Cancer patients have little opportunity to save for the
Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
Transplant First: Addressing inequality in access to Kidney Transplantation in the West Midlands
Project Mandate Transplant First: Addressing inequality in access to Kidney Transplantation in the West Midlands West Midlands Cardiovascular Strategic Clinical Network Project Mandate Transplant First:
Community Health Workers (CHWs) in HIV Services: Insights from Virginia. November 16, 2017
Community Health Workers (CHWs) in HIV Services: Insights from Virginia November 16, 2017 1 Welcome Allyson Baughman, MPH Program Manager, Center for Innovation in Social Work and Health Boston University
Care of HIV Infected People
Care of HIV Infected People Patrick Ndase, MD, MPH MTN Annual Meeting Marriott Key Bridge, Arlington, VA April 21-23, 2008 Why Care for HIV infected in such a meeting? Site Core Community Why Care for
The CQUIN Learning Network
The CQUIN Learning Network Adolescents Living with HIV: Innovations and Experience Shenaaz Pahad Wits Reproductive Health and HIV Institute October 24-27, 2017 Johannesburg, South Africa Why adolescents
Vacancy Announcement: Situational Analysis on the Status of Sexual and Reproductive Health of students in tertiary institutions in the SADC Region
Vacancy Announcement: Situational Analysis on the Status of Sexual and Reproductive Health of students in tertiary institutions in the SADC Region Individual Consultant/Consultancy Firm Contract Duration:
Counselling at Melbourne IVF
Counselling at Melbourne IVF Mandatory Pre-treatment counselling Counselling is a legislative requirement in Victoria for all people (including your partner) prior to commencing any fertility treatment.
California Department of Public Health (CDPH), Office of AIDS (OA) Monthly Report April 2018
California Department of Public Health (CDPH), Office of AIDS (OA) Monthly Report April 2018 Please note: As part of OA s ongoing work to align all of our work and communications with Laying a Foundation
Participatory Community Mapping February Trial Site GPP File. 1 v22aug11
February 2014 Trial Site GPP File 1 v22aug11 Background The Microbicides Development Programme (MDP) Phase III trial (MDP 301) of the candidate vaginal microbicide PRO2000 1, 2 3, 4, 5, 6 used innovative
AFFIRM Annual Newsletter
Supported by Alan J Flisher Centre for Public Mental Health 26 October 2012 Volume 1, Issue 1 AFFIRM Annual Newsletter African Partners WHAT IS AFFIRM? The AFrica Focus on Intervention Research for Mental
Dr. med. H. Schulte, Dr. med. J. Abel und Dr. med. K. Jahn are licensed to perform medical examinations for USA, Canada, Australia and New Zealand.
IMMIGRATION MEDICALS Dr. med. H. Schulte, Dr. med. J. Abel und Dr. med. K. Jahn are licensed to perform medical examinations for USA, Canada, Australia and New Zealand. For further information please contact